Project Description

Concarlo
An Opportunity To Join The Fight Against Metastatic Breast Cancer

Date & Time:

September 22, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Today, a diagnosis of metastatic breast cancer is essentially a death sentence. While CDK Inhibitors can prolong life, 40% of patients don’t respond to current treatments and 100% will become resistant after a short period of time. Thanks to Concarlo, that could change very soon.

Concarlo is a women-lead biotech oncology company focused on diagnosing and treating metastatic breast cancer by targeting a unique cellular pathway. Their lead drug, IpY essentially serves as an off switch for CDK4/6 and CDK2 complexes, blocking tumor growth and preventing remission.

Their approach has been validated by several publications, an NIH SBIR Phase I award, and a contract with the NIH Nanoparticle Characterization Laboratory. In small animal testing, IpY demonstrated greatly increased survivability with tumor regression and no toxicity.

Join our webinar to hear from Concarlo’s CEO and CSO, Dr. Stacy Blain, and COO, LisaMarie Casey, as they discuss the science behind this remarkable breakthrough in the treatment of metastatic breast cancer.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.